Skip to the stories
Wednesday, 18 November 2026
Saved

Next edition

18:13

Headlines

Top Stories

FDA approves new Roche breast cancer drug Wilserdly

United States regulators approved a new breast cancer drug called Wilserdly on Monday, expanding treatment options and providing a major product launch for pharmaceutical manufacturer Roche.

FTMQ Health, written by our newsroom0 views

Share
Picture: STAT News

The United States Food and Drug Administration approved a new breast cancer drug named Wilserdly on Monday, STAT News reported. The medication, which is also known as giredestrant, is manufactured by the Swiss pharmaceutical company Roche. [1]

STAT News reported that Roche considers the regulatory decision one of its most critical milestones. The company has stated that the new medicine has the potential to become its highest-selling product to date while expanding its existing lineup of breast cancer treatments. [1]

Oncology therapies form a core component of the business, accounting for approximately 34 percent of the company's pharmaceutical revenues. Its cancer product portfolio includes other treatments such as Avastin and Tecentriq. [3]

The approval gives Roche a broader foothold in the field of breast cancer care, STAT News reported. The company plans to move forward with the commercial launch of the medication following the regulatory clearance. [1]

Share

In short

  • The FDA approved the new breast cancer drug Wilserdly on Monday.
  • Wilserdly is also known by the scientific name giredestrant.
  • Roche manufactures the medication and expects it could become its top-selling product.

Sources

Every paragraph above points to the numbered items it rests on. Read the originals here.

  1. [1]STAT+: FDA approves new breast cancer drug, providing new option for some patients, boost for RocheSTAT News, 1d ago (the report this story comes from)

Background

  1. [2]Atezolizumab on Wikipedia
  2. [3]Roche on Grokipedia
  3. [4]Japan approves pitolisant for excessive daytime sleepiness in narcolepsy and sleep apnea FTMQ Health, 44d ago
  4. [5]Advanced training fails to boost sudden cardiac arrest survival rates FTMQ Health, 9d ago

Our newsroom writes these reports with the help of software, from the 5 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.

Earlier reports of ours on the same people and subjects.

More in Top Stories

Get the day in one email

Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.

By signing up you agree to our terms and privacy policy. Unsubscribe any time.

Comments

Loading

Join the conversation

Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.

Already on the list? Enter the same address and we will send a sign-in link.

By signing up you agree to our terms and privacy policy. Unsubscribe any time.